Warp Sciences Launches to Automate Drug Discovery Labs

The startup raised $215 million to train robots for chemical synthesis and reduce reliance on offshore labs.

Updated on Oct. 22, 2026 in Artificial Intelligence

Bold flat-color editorial illustration depicting a single robotic arm and beaker, illustrating automated laboratory infrastructure for drug discovery. — Warp Sciences, an AI startup led by Kevin Weil, has raised $215 million to automate pharmaceutical laboratory discovery through robotic chemical synthesis. AI Illustration. Upload story photo >

Live Poll

Do you believe replacing human chemists with autonomous robots will lead to better drug discovery outcomes?

Kevin Weil has launched Warp Sciences, an artificial intelligence startup that uses robotics to automate laboratory processes for drug discovery. The company has announced $215 million in new funding at an $865 million valuation.

Why it matters

Warp Sciences aims to accelerate pharmaceutical development by utilizing 24-hour robotic operation cycles. The startup also intends to reshore laboratory infrastructure to the United States to reduce geopolitical supply-chain risks associated with current outsourcing models.

The firm operates on a $215 million funding round and an $865 million valuation. Its automation architecture relies on human chemists wearing camera-equipped sensor gloves to train robots for the manual execution of laboratory tasks.

The players

Kevin Weil

Founder of Warp Sciences and former executive with extensive experience in scaling technology-heavy operations.

Warp Sciences

An AI-native startup focused on automating drug discovery workflows through sensor-trained robotic systems.

Lightspeed

A venture capital firm that led the $215 million funding round and specializes in early-stage technology investments.

The details

The platform functions by capturing human physical movements via cameras and sensor gloves, which are then used to program robotic arms to perform repetitive laboratory workflows. These robots then synthesize and test drug compounds around the clock. This system aims to bypass the constraints of human-operated, shift-based lab hours while minimizing reliance on foreign outsourcing hubs.

October 22, 2026: Warp Sciences officially launched and announced its $215 million funding round.

The Tech Race

This development represents a shift toward local, automated drug discovery as a counter to the industry-wide reliance on laboratory outsourcing to China. The startup competes by attempting to replace manual, shift-based lab work with continuous, data-driven robotics.

For pharmaceutical researchers and biotech developers, this platform signals a potential move toward automated laboratory workflows that could eventually decrease development timelines. Access to these robotic capabilities and the specific cost structure for drug discovery partners remain unannounced.

The takeaway

Warp Sciences highlights a significant effort to automate the manual bottleneck of drug compound synthesis. Industry observers should watch for the company's first published performance benchmarks regarding the speed and accuracy of its robot-trained chemical testing.